OTCMKTS:HLUYY - H. Lundbeck A/S- Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$28.41
▼ -0.27 (-0.94%)
1 month | 3 months | 12 months
Get New H. Lundbeck A/S- Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLUYY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLUYY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for H. Lundbeck A/S- in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $28.41.
Hold
The current consensus among 6 contributing investment analysts is to hold stock in H. Lundbeck A/S-.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/8/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/6/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetDetails
10/16/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
10/13/2020BarclaysReiterated RatingOverweight
i
9/15/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral
i
8/21/2020AlphaValueDowngradeBuy
i
8/17/2020UBS GroupReiterated RatingBuy
i
8/14/2020Credit Suisse GroupReiterated RatingUnderperform
i
8/14/2020BarclaysReiterated RatingOverweight
i
3/4/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
1/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
12/14/2018BarclaysUpgradeEqual Weight ➝ Overweight
i
11/12/2018SVB LeerinkInitiated CoverageMarket Perform
i
Rating by K. Goodreau at SVB Leerink LLC
5/3/2018DNB MarketsDowngradeBuy ➝ Sell
i
7/28/2017Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
i
4/12/2017Jefferies Financial GroupDowngradeBuy ➝ Hold
i
4/11/2017Jefferies Financial GroupDowngradeBuy ➝ Hold
i
8/31/2016Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
i
2/11/2016DNB MarketsUpgradeHold ➝ Buy
i
1/5/2016JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
(Data available from 10/29/2015 forward)
H. Lundbeck A/S- logo
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S was founded in 1915 and is headquartered in Valby, Denmark.
Read More

Today's Range

Now: $28.41
$28.00
$28.45

50 Day Range

MA: $32.34
$28.68
$34.20

52 Week Range

Now: $28.41
$25.68
$44.60

Volume

15,003 shs

Average Volume

3,457 shs

Market Capitalization

$5.66 billion

P/E Ratio

22.20

Dividend Yield

1.46%

Beta

0.65